Compare Amylx Pharmaceuticals Inc (AMLX) vs Deere & Company (DE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Deere & Company — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Deere & Company trades at $586.86 (market cap $158.42B). The key difference: Deere & Company is far larger — about 80× Amylx Pharmaceuticals Inc's market cap, and Deere & Company pays a 1.1% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DE | |
|---|---|---|
Market Cap | $1.98B | $158.42B |
Sector | Health | Industrials |
52-Week High | $18.70 | $662.49 |
52-Week Low | $7.64 | $439.11 |
Enterprise Value | $1.70B | $213.24B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Deere & Company (DE) trades at $586.86, down 1.02% on the day, near the lower end of its 52-week range. The stock shows a bullish technical signal with recent earnings beats but faces revenue declines from $60.2B in 2023 to $44.7B in 2025. Analyst consensus is mixed with a $689.30 price target, and the company maintains strong cash flow from operations of $7.46B in 2025.
The outlook hinges on agricultural sector recovery and precision farming growth, offering potential upside if earnings stabilize. Risks include cyclical demand, high debt levels, and margin pressure from declining net income. Investor sentiment is cautious amid volatile farm economics, yet institutional holdings suggest long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
